About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

NCT00493324·7 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Astellas Pharma Inc

This is a 1 arm study designed to evaluate the immune response to pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Subject has chronic plaque psoriasis
Subject has at least 5% body surface area affected with psoriasis

You may not be if

Skin disorder other than plaque psoriasis in affected area
Previously immunized with any pneumococcal vaccine
Subject has pustular or erythrodermic psoriasis
Subject is immunocompromised
Six or more herpes simplex virus outbreaks per year
History or malignancy, chronic serious infection or hepatic disease

The record

StatusCompleted

PhasePhase 4

Taking part43

StartedJul 2007

UpdatedFeb 2, 2012

Conditions

Chronic Plaque Psoriasis

Where7

Birmingham, Alabama, United States
San Diego, California, United States
New York, New York, United States